Nanjing Runtong Changda Pharmaceutical Technology

Nanjing Runtong Changda Pharmaceutical Technology is a clinical-stage biotechnology company based in Nanjing, China, focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company's primary research efforts are directed toward high-prevalence conditions such as hyperuricemia, gout, and non-alcoholic steatohepatitis (NASH). Its lead candidate, RTCD-01, is a potent URAT1 inhibitor designed to lower serum uric acid levels and is currently undergoing clinical evaluation. Runtong Changda aims to address significant unmet medical needs in the metabolic space through its internal R&D capabilities and strategic clinical development. The firm operates primarily within the Jiangbei New Area high-tech pharmaceutical cluster.